Roth/MKM lowers IMAX stock price target on China headwinds By Investing.com

Roth/MKM cut its IMAX price target to $44 from $46 while keeping a Buy rating, citing a modestly lower 2026 EBITDA forecast and elevated valuation, including a high P/E versus near-term growth. The firm still sees strong first-quarter box office performance outside China, expects further market share gains through 2026, and says the $1.4 billion global box office guide remains reasonable. Separately, IMAX reported Q1 global box office revenue of $260 million versus Benchmark’s $269 million estimate, and CEO Richard Gelfond is on medical leave for pneumonia treatment.

Analysis

The clean read is that IMAX is still a share-gain story, but the market is now paying up for a path that is increasingly dependent on the back half of the year. That creates a timing mismatch: the equity can stay supported on upgraded industry confidence, yet the next leg higher likely needs proof that non-China demand can absorb a softer China comp set without margin giveback. In other words, the stock is less about absolute box office and more about whether the company can keep monetizing premium formats at a faster rate than the consensus is modeling.

The second-order winner is the broader premium theatrical ecosystem: exhibitors with format exposure, content owners with tentpole slates, and licensors that benefit from higher per-screen economics. The loser is anyone implicitly anchored to China as the primary growth engine, because this setup is making the business look more geographically diversified while simultaneously reminding investors that one region can still dominate quarterly variance. That usually compresses the multiple only when the market stops believing the diversification story; until then, the valuation premium can persist longer than fundamentals suggest.

The governance overhang is a real but currently underpriced catalyst risk. Management absence matters less for day-to-day operations than for signaling during a period when investors are underwriting a multi-quarter acceleration; any delay in commentary, guidance confidence, or event participation can widen the discount rate applied to a richly priced name. The contrarian view is that consensus may be overfocusing on the raised target prices and underestimating how much of the 2026 narrative is already embedded in a stock trading on expectations of continued market-share gains rather than near-term earnings delivery.

Key Decisions for Investors

• Fade strength in IMAX on rallies into the next 2-4 weeks via a small short or call spread, because the near-term setup is more about multiple support than earnings reacceleration; cover if management commentary restores confidence in H2 share gains.
• Pair long IMAX with a short in a lower-quality theatrical/media name over 1-3 months to isolate premium-format share capture versus broader sector beta; this reduces box-office demand risk while keeping exposure to the secular format thesis.
• If already long IMAX, trim 20-30% ahead of the next earnings/event window and re-add only on evidence that non-China growth offsets Asia volatility; the risk/reward improves materially after confirmation rather than before it.
• Use options rather than outright equity for upside exposure: buy 3-6 month call spreads on IMAX to express the H2 catalyst without paying full multiple risk; the thesis is good, but the valuation leaves limited room for a clean multiple expansion.
• Watch for a volatility event around CEO-health headlines and any guidance updates; if implied volatility spikes without fundamental deterioration, sell premium rather than chase direction, since the stock is likely to mean-revert if execution remains intact.